Non disponible en dehors du Royaume-Uni et de l'Irlande
Biochem/physiol Actions
Cinaciguat, also known as BAY 58-2667, is a novel activator of guanylate cyclase. It is used in the treatment of acute decompensated heart failure (ADHF). It has been reported that cinaciguat possesses cardiovascular effects.
Cinaciguat activates sGC (soluble guanylate cyclase) independently of NO. Cinaciguat binds to sGC′s NO-sensory H-NOX domain when it is heme-depleted. Also, the compound Cinaciguat protects sGC from oxidation-induced ubiquitin-triggered degradation.
Packaging
5, 25 mg in glass bottle
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :